ClinicalTrials.gg
RecruitingNCT06726148Updated Aug 27, 2026

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

A Phase 1/2 interventional study of ECI830 and ribociclib in Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors and Extensive-stage Small Cell Lung Cancer, sponsored by Novartis Pharmaceuticals. Recruiting at 33 sites in 16 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Small Cell Lung Carcinoma by Novartis — 4 open to participants now, 5 under way, none of them phase 3. Small Cell Lung Carcinoma · Novartis.

Planned enrollment
2nd of 13
280 · median 80
Started
2025
with 1 other
Phase 1/2
3 of 14
2 open now
Registered
11th of 14
by date

Among the 14 studies in Small Cell Lung Carcinoma by Novartis, this one is the 2nd largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 in phase 1/2, and was the 11th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

4 of the 14 studies in Small Cell Lung Carcinoma by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Small Cell Lung Carcinoma by Novartis, or all of them as a file.
02

Study summary

Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies.

Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.

Read the detailed description

This is a first-in-human, open-label, phase I/II, multi-center study consisting of an ECI830 single agent treatment arm in patients with advanced HR+/HER2- breast cancer or other advanced solid tumors harboring CCNE1 amplification or extensive-stage small cell lung cancer (ES-SCLC), and a combination treatment arm of ECI830 with ribociclib and fulvestrant in patients with advanced breast cancer. Single agent escalation may be followed by an expansion part stratified by disease indication. The escalation of the combination arm may continue into a randomized, open label, Phase II with optional dose optimization in advanced breast cancer patients.

03

Conditions studied

  • Advanced HR+/HER2- Breast Cancer
  • Advanced CCNE1-amplified Solid Tumors
  • Extensive-stage Small Cell Lung Cancer

Keywords

  • ECI830
  • Ribociclib
  • Fulvestrant
  • Breast cancer
  • CCNE1 amplification
  • Small cell lung cancer
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age ≥ 18 years old.

Patients with one of the following indications:

Phase I:

HR+/- aBC with disease progression on or following at least one line of hormone-based therapy in combination with a CDK4/6i and at least one additional for disease.

and/or cytologically confirmed diagnosis of locally advanced or metastatic cancer with a CCNE1 amplification. For dose expansion only: no more than 3 prior lines of therapy for advanced or metastatic disease.

Patients with ES-SCLC and disease progression on or after standard of care (SoC). For dose expansion only: no more than 2 prior lines of therapy for advanced or metastatic disease are allowed.

Phase II:

HR+/HER2- aBC with disease progression on an aromatase inhibitor or tamoxifen in combination with a CDK4/6 inhibitor for unresectable/metastatic disease with no more than 2 lines of endocrine therapy.

as determined by v1.1.

BC only: If no measurable disease is present, then at least one predominantly lytic bone lesion must be present that can be accurately assessed at baseline and is suitable for repeated assessment.

Exclusion criteria

Exclusion Criteria:

Previous treatment with a CDK2 inhibitor at any time.

Patients with inadequate bone marrow and/or organ functions with out-of-range laboratory values.

, uncontrolled heart disease and/or cardiac repolarization abnormality including MI, CABG, long syndrome, or risk factors for TdP.

Presence of symptomatic or CNS metastases that require local therapy or increasing doses of within 2 weeks prior to study entry.

For the combination treatment:

Patients with symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine-based therapy.

Patients who could not tolerate the prescribed dose of ribociclib during a previous course of treatment, requiring dose reduction or permanent discontinuation due to adverse events.

For patients with BC: Patient is concurrently using hormone replacement therapy.

who are unwilling to use highly effective methods, pregnant or nursing women.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    ECI830 Single Agent (Arm A)

    Phase I

    Drug: ECI830

  • Experimental
    Dose Escalation Combination ECI830 + ribociclib + fulvestrant (Arm B)

    Phase I

    Drug: ECI830 · Drug: ribociclib · Drug: fulvestrant

  • Experimental
    Ribociclib in combination with fulvestrant (Arm C)

    Phase II

    Drug: ribociclib · Drug: fulvestrant

  • Experimental
    ECI830 in combination with fulvestrant (Arm D)

    Phase II

    Drug: ECI830 · Drug: fulvestrant

  • Experimental
    ECI830 in combination with ribociclib and fulvestrant (Arm E)

    Phase II

    Drug: ECI830 · Drug: ribociclib · Drug: fulvestrant

  • Experimental
    ECI830 in combination with ribociclib and fulvestrant (Arm F)

    Phase II

Interventions

  • DrugECI830

    Experimental

  • Approved medication

    Also known as: Kisqali

  • Approved medication

    Also known as: Faslodex

06

What researchers measure

Primary outcomes

  1. Phase I: Incidence of dose-limiting toxicities (DLTs)

    A DLT is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 assessed as unrelated to disease, disease progression, inter-current illness or concomitant medications that occurs within the first 28 days of treatment. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher.

    Time frame: 2 years

  2. Phase I: Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Number of participants with AEs and SAEs by treatment group, including changes in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs.

    Time frame: 2 years

  3. Phase I: Number of participants with dose interruptions, reductions and discontinuations

    Assessment of tolerability. For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments are permitted in order to allow patients to continue the study treatment.

    Time frame: 2 years

  4. Phase II: PFS rate at 6 months per local response evaluation criteria in solid tumors (RECIST) v1.1

    Progression Free Survival (PFS) rate at 6 months is defined as the proportion of patients who are alive and progression-free per RECIST v1.1 at 6 months.

    Time frame: 6 months

Secondary outcomes

  1. Phase I and II: Area under the plasma concentration-time curve (AUC) of ECI830 and ribociclib

    Pharmacokinetic (PK) parameters calculated based on ECI830 and ribociclib plasma concentrations by using non-compartmental methods.

    Time frame: From pre-dose up to 24 hours post-dose in Cycle 1. One cycle=28 days.

  2. Phase I and II: Maximum observed plasma concentration (Cmax) of ECI830 and ribociclib

    PK parameters calculated based on ECI830 and ribociclib plasma concentrations by using non-compartmental methods.

    Time frame: From pre-dose up to 24 hours post-dose in Cycle 1. One cycle=28 days.

  3. Phase I and II: Best overall response (BOR) per RECIST v1.1

    BOR per RECIST v1.1 is defined as the best overall confirmed response recorded from the start of the treatment until progressive disease (PD), death, start of new therapy, withdrawal of consent or end of study, whatever comes first.

    Time frame: 2 years

  4. Phase I and II: Overall response rate (ORR) per RECIST v1.1

    ORR per RECIST v1.1 is defined as the proportion of patients with a BOR of Complete response (CR) or Partial response (PR) according to RECIST v1.1 as per local review.

    Time frame: 2 years

  5. Phase I and II: Disease control rate (DCR) per RECIST v1.1

    DCR per RECIST v1.1 is defined as the proportion of patients with a BOR of CR, PR, or Stable disease (SD) according to RECIST v1.1 as per local review.

    Time frame: 2 years

  6. Phase I and II: Clinical benefit rate (CBR) per RECIST v1.1

    CBR per RECIST v1.1 is defined as the proportion of patients with a BOR of CR, PR, or an overall lesion response of SD or Non-CR/Non-PD which lasts for at least 24 weeks according to RECIST v1.1 as per local review.

    Time frame: 2 years

  7. Phase I and II: Progression Free Survival (PFS) per RECIST v1.1

    PFS is defined as the time from the date randomization to the date of the first documented progression or death due to any cause.

    Time frame: 2 years

  8. Phase II: Duration of Response (DOR) per RECIST v1.1

    DOR per RECIST v1.1 is the time between the first documented response (CR or PR) and the date of progression or death due to any cause.

    Time frame: 2 years

  9. Phase II: Overall Survival (OS)

    OS is defined as the time between the date of randomization to the date of death due to any cause.

    Time frame: 2 years

  10. Phase II: Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Number of participants with AEs and SAEs by treatment group, including changes in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs.

    Time frame: 2 years

  11. Phase II: Number of participants with dose interruptions, reductions and discontinuations

    Assessment of tolerability. For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments are permitted in order to allow patients to continue the study treatment.

    Time frame: 2 years

07

Study locations

33 of 33 sites recruiting
  • University of California LA
    Los Angeles, California 90095, United States
    Recruiting
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
    Recruiting
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
    Recruiting
  • WA Uni School Of Med
    St Louis, Missouri 63110, United States
    Recruiting
    • Mary Halim · Contactmaryh@wustl.edu · +1 314 362 7249
    • Cynthia Ma · Principal investigator
  • Memorial Sloan Kettering
    New York, New York 10017, United States
    Recruiting
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
    Recruiting
  • MD Anderson Cancer Center Uni of Te
    Houston, Texas 77030, United States
    Recruiting
  • Fred Hutch Cancer Research
    Seattle, Washington 98109, United States
    Recruiting
    • Ly Tieng Huot · Contactlhuot@fredhutch.org · +1 206288 1382
    • Sara Hurvitz · Principal investigator
  • Novartis Investigative Site
    Clayton, Victoria 3168, Australia
    Recruiting
  • Novartis Investigative Site
    Melbourne, Victoria 3004, Australia
    Recruiting
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
  • Novartis Investigative Site
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
  • Novartis Investigative Site
    Nanjing, Jiangsu 210029, China
    Recruiting
  • Novartis Investigative Site
    Xian, Shanxi 710061, China
    Recruiting
  • Novartis Investigative Site
    Brno, 656 53, Czechia
    Recruiting
  • Novartis Investigative Site
    Copenhagen, 2100, Denmark
    Recruiting
  • Novartis Investigative Site
    Odense C, 5000, Denmark
    Recruiting
  • Novartis Investigative Site
    Bordeaux, 33076, France
    Recruiting
  • Novartis Investigative Site
    Saint-Herblain, 44805, France
    Recruiting
  • Novartis Investigative Site
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
    Recruiting
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
    Recruiting
  • Novartis Investigative Site
    Ulm, 89081, Germany
    Recruiting
  • Novartis Investigative Site
    Haifa, 3109601, Israel
    Recruiting
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
    Recruiting
  • Novartis Investigative Site
    Milan, MI 20141, Italy
    Recruiting
  • Novartis Investigative Site
    Modena, MO 41124, Italy
    Recruiting
  • Novartis Investigative Site
    Chuo Ku, Tokyo 1040045, Japan
    Recruiting
  • Novartis Investigative Site
    Singapore, 119074, Singapore
    Recruiting
  • Novartis Investigative Site
    Seoul, Seoul 03080, South Korea
    Recruiting
  • Novartis Investigative Site
    Barcelona, 08035, Spain
    Recruiting
  • Novartis Investigative Site
    Barcelona, 08036, Spain
    Recruiting
  • Novartis Investigative Site
    Tainan, 704, Taiwan
    Recruiting
  • Novartis Investigative Site
    London, Oxford OX3 7LE, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Sep 2028, 41 months after the start.

Of 71 industry-sponsored phase 1/2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 74. This study's planned 41 months is below that.

Counting every sponsor, half of 98 studies reached it within 54 months; a quarter within 44 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2024
First posted
Dec 10, 2024
StartActual
Apr 3, 2025
Primary completionEst.
Sep 25, 2028
CompletionEst.
Sep 25, 2028
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06726148
Responsible party
Sponsor
First posted
Dec 10, 2024
Start date
Apr 3, 2025
Primary completion
Sep 25, 2028 (estimated)
Completion
Sep 25, 2028 (estimated)
Last update
Aug 27, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion